Golden State Equity Partners’s iRadimed IRMD Stock Holding History

Golden State Equity Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.69K	Buy	+28	New	+$2.8K	﹤0.01%	1606

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Golden State Equity Partners's IRMD Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in iRadimed (IRMD) in Q1 2026: 28 shares worth $2.69K. The stake represents ﹤0.01% of the portfolio and ranks #1606 among its holdings.

228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Golden State Equity Partners held 28 shares of iRadimed worth $2.69K as of Q1 2026.
iRadimed was a new Golden State Equity Partners position in Q1 2026.
iRadimed made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1606 holding.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.